Roquefort Therapeutics (LON:ROQ) Stock Price Up 12% – Time to Buy?

Roquefort Therapeutics plc (LON:ROQ) shares rose 12% during mid-day trading on Tuesday . The stock traded as high as GBX 4.20 ($0.05) and last traded at GBX 4.20 ($0.05). Approximately 1,302,970 shares were traded during trading, a decline of 0% from the average daily volume of 1,308,735 shares. The stock had previously closed at GBX 3.75 ($0.05).

Roquefort Therapeutics Stock Performance

The business’s fifty day moving average is GBX 4.05 and its two-hundred day moving average is GBX 4.04. The stock has a market capitalization of £4.69 million, a PE ratio of -363.30 and a beta of 0.05. The company has a quick ratio of 3.07, a current ratio of 0.79 and a debt-to-equity ratio of 12.37.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.